Cook Pharmica teams with cell line development firm Selexis

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Cell line development, Cell culture, Biotechnology

Cook Pharmica teams with cell line development firm Selexis
Cook Pharmica and Selexis claim their combined service offering will help biopharmas scale up mAb and biosimilars production faster and more cheaply.

Under the new partnership – financial terms of which were not disclosed – Selexis will provide mammalian CHO cell line development after which Cook will provide process development, manufacturing and final packaging services.

The firms have already completed a 9-month pilot project for the production of a monoclonal antibody (mAb) in which they achieved titres of more than 3.5g per litre in 20l bioreactors according to Cook chief scientific officer, Vic Vinci.

These preliminary data from the proof-of-concept confirmed our ability in this case study to create a reliable process for the transfer and scale-up of a high expressing, stable clonal cell line, via a technology platform approach, that yielded commercial-ready titers with minimal development under the conditions of the study​.”

He added that: “In addition to this proof-of-concept program, we are very experienced in working with Selexis cell lines and are excited to be collaborating more with the Selexis team in the near future​.”

Protein expression

Selexis’ cell line development business focus on its Suretechnology platform, which is a system used to insert genes into CHO cells and other mammalian cell lines for biopharmaceutical applications.

The technology – which uses novel DNA-based elements to control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins – is being used in a variety of programs from drug discovery to late-stage clinical trials.

Selexis' cell line laboratory and production capacity are based at a facility in Geneva, Switzerland, which also houses protein purification technology unit for the production of development-scale batches.

Related news

Show more

Related products

show more

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Related suppliers

Follow us


View more